STOK
Stoke Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$24.82
+2.69%Oct 5, 2026, 11:00 UTC
Stoke Therapeutics completed a successful meeting with the U.S. FDA to align on key aspects of a planned U.S. New Drug Application for zorevunersen, its investigational treatment for Dravet syndrome.
Source:Sep 25, 2026, 20:37 UTC
Alexander (Bo) Cumbo was appointed as a Class III director of Stoke Therapeutics, effective September 23, 2026.
Sep 25, 2026, 20:37 UTC
Edward M. Kaye, M.D. resigned as a Class III director of Stoke Therapeutics, effective September 23, 2026.
Aug 20, 2026, 07:24 UTC
Bank of America Corp DE increased its stake in Stoke Therapeutics, Inc. by 163.4% during the first quarter, buying an additional 336,931 shares, according to a recent SEC filing.
Source:Aug 3, 2026, 22:04 UTC
Stoke Therapeutics announced that its Phase III EMPEROR study of zorevunersen in Dravet syndrome patients remains on track for a data readout in Q3 2027, following completion of enrollment ahead of the planned rolling NDA submission.
Aug 3, 2026, 20:01 UTC
Stoke Therapeutics reported its financial results for the second quarter ended June 30, 2026, and provided business updates including progress of its global Phase program for zorevunersen in Dravet syndrome.
Jun 30, 2026, 12:00 UTC
Stoke Therapeutics completed enrollment of 162 patients into the Phase 3 EMPEROR study of zorevunersen, an investigational medicine for Dravet syndrome.
Source: